A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (RELEVANCE)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2012 by The Lymphoma Academic Research Organisation
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
The Lymphoma Academic Research Organisation
ClinicalTrials.gov Identifier:
NCT01650701
First received: July 24, 2012
Last updated: NA
Last verified: July 2012
History: No changes posted
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2024
  Estimated Primary Completion Date: June 2024 (Final data collection date for primary outcome measure)